▶ SELANK · SUBTOPIC · DOSING LITERATURE
SELANK Dosing Literature
For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.
SCOPE OF THIS PAGE
This page documents the published-literature dose ranges that appear in trials and animal studies of SELANK. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.
ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH
The published research record for SELANK reports the following route(s) of administration: Intranasal (registered Russian protocol), Subcutaneous (research). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of SELANK.
PHARMACOKINETIC HALF-LIFE
Published pharmacokinetic data report a half-life for SELANK of approximately Short (minutes) plasma; intranasal retention longer. Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.
CITED DOSE RANGES IN THE LITERATURE
The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of SELANK. Refer to the original publication for full protocol detail.
- Kozlovskaya MM, Kozlovskii II, Val'dman EA, Seredenin SB (2003) reports the SELANK protocol used in Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress, published in Neurosci Behav Physiol. See the source for the protocol-level dose range, frequency, and duration. link
- Vyunova TV, Andreeva LA, Shevchenko KV, Myasoedov NF (2018) reports the SELANK protocol used in Synthetic Peptides as Promising Anxiolytics of New Generation: Experimental and Clinical Justification, published in Acta Naturae. See the source for the protocol-level dose range, frequency, and duration. link
DOSING Q+A FROM LITERATURE
The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.
▶ How is Selank administered in Russian clinical practice?
The Russian-approved formulation is a 0.15% intranasal solution. Clinical literature describes 2–3 drops per nostril, 2–3 times per day. This wiki does not recommend any human dose.
▶ Side effects of Selank?
Limited Western safety data. Russian literature describes mild nasal irritation and rare headache at standard intranasal doses.
▶ How does Selank compare to benzodiazepines?
Russian preclinical literature describes anxiolytic activity in rodent elevated-plus-maze and conditioned-suppression paradigms, with potency comparable to short-acting benzodiazepines at the doses tested. Without GABA-A direct binding, Selank theoretically lacks the dependence and withdrawal profile of benzodiazepines · though this is not validated by Western RCT.
STORAGE OF THE REFERENCE COMPOUND
Lyophilized · 4 °C 12+ months
Reconstituted · 2–8 °C, 28 days
Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.
RECONSTITUTION MATH (CALCULATOR)
The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.
REGULATORY CONTEXT
FDA · Not FDA-approved. Research-use only in the United States.
WADA · Not currently listed on the WADA Prohibited List (2026).
RELATED PAGES
▶ LAST UPDATED · 2026-05-19